India’s first intranasal Covid vaccine by Bharat Biotech received approval from the Drug Controller General of India (DCGI) for primary immunization against the injection for people above the age of 18. It is India’s first nasal vaccine for COVID-19. The Union Minister of Health and Family Welfare Mansukh Mandaviya termed the vaccine a ‘Big Boost’ to India’s fight against COVID-19.
Bank Maha Pack includes Live Batches, Test Series, Video Lectures & eBooks
Bharat Biotech International Limited (BBIL), is a global leader in vaccine innovation and developer of vaccines for infectious diseases. The BBIL announced that the development of the Intranasal COVID vaccine (BBV154), has been approved for restricted use in an emergency. The iNCOVACC, is a recombinant replication-deficient adenovirus vectored vaccine with a pre-fusion stabilized spike protein. This vaccine was evaluated in phases I, II, and III, clinical trials with successful results. The vaccine was formulated to allow Intranasal delivery through nasal drops. It is designed to be cost-effective in low and middle-income countries.
Since the time of the first summit held in 2009, there has been much change…
The group of BRICS countries has grown considerably, with 11 leading emerging economies belonging to…
As India is organizing the 18th BRICS Summit in New Delhi from September 12 to…
The Reserve Bank of India (RBI) has come up with an innovative digital payment features…
India’s New Delhi is all set to host the BRICS Summit 2026 on September 12…
West Bengal is the only Indian state that has international boundaries with the countries of…